
|Articles|November 13, 2014
- NSCLC (Issue 5)
- Volume 5
- Issue 1
The Future of Squamous Cell Lung Cancer Treatment
Author(s)Peter Hammerman, MD, PhD
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Advertisement
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Learn more about the treatment of squamous cell lung cancer > >
Articles in this issue
about 11 years ago
Veliparib Shows Potential in Squamous Cell NSCLCabout 11 years ago
IDO Inhibitors May Augment Immunotherapy in NSCLCabout 11 years ago
Multidisciplinary Teams in NSCLC Important for Optimal Patient Careabout 11 years ago
The Role of Chemotherapy in the Treatment of Lung Cancerabout 11 years ago
The Challenges of Treating Lung Cancerabout 11 years ago
Early Detection and Molecular Testing Evolving for NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































